Immunotherapy Keeps 87-year-old Man on the Job
Vanderbilt University Medical CenterFive-year survival data for pembrolizumab patients with advanced non-small cell lung cancer were presented June 1 at the 2019 ASCO Annual Meeting, May 31-June 4, in Chicago. The study results showed a marked improvement over 5-year survival rates in the pre-immunotherapy era, which averaged only 5.5%. Pembrolizumab increased the survival rate to 23.2% after five years in people with advanced non-small cell lung cancer who had not previously been treated with chemotherapy and to 15.5% in those who had been previously treated with chemotherapy. The KEYNOTE-001 is the longest follow-up study to date of people with advanced non-small cell lung cancer treated with pembrolizumab.